BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Часто задаваемые вопросы
В каком секторе работает BioLife Solutions Inc (BLFS)?
BioLife Solutions Inc относится к сектору Здравоохранение.
Какова текущая цена акций BioLife Solutions Inc (BLFS)?
По последним данным, цена акций BioLife Solutions Inc составляет 38,49 $, предыдущее закрытие — 38,58 $. За последнюю торговую сессию акции BioLife Solutions Inc снизились на -0,09 $, что соответствует падению на -0,23%.
Выплачивает ли BioLife Solutions Inc (BLFS) дивиденды?
Нет, BioLife Solutions Inc не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у BioLife Solutions Inc (BLFS)?
У компании BioLife Solutions Inc бета 1.896, что указывает на повышенную волатильность по сравнению с рынком.